The extracellular miRNAs circulate in the bloodstream and may serve as novel diagnostic and therapeutic biomarkers. The aim of the present study was to investigate circulating Toll-like receptor 4 (TLR4)-responsive miRNA expression in patients with coronary artery disease (CAD) and to examine the effects of renin–angiotensin system (RAS) blockade and statins on miRNA levels. This study included 41 patients with CAD and 20 subjects without CAD (non-CAD). Plasma TLR4-responsive miRNA samples were analysed using a microarray assay for 1700 human miRNA. The candidate miRNAs were verified with real-time reverse transcription (RT)-PCR. Patients with CAD were randomized to 12 months of combined treatment with either telmisartan and atorvastatin [angiotensin II receptor blocker (ARB)] or enalapril and atorvastatin [angiotensin-converting enzyme inhibitor (ACEI)]. Plasma samples were obtained from peripheral blood at baseline and after 12 months. The microarray assay showed significant differences in seven TLR4-responsive miRNAs between the CAD and non-CAD groups (P<0.05). Real-time PCR verified that miR-31, miR-181a, miR-16 and miR-145 were significantly lower in the CAD group than in the non-CAD group (P<0.01). Levels of TLR4 protein were higher in the CAD group than in the non-CAD group (P<0.01) and were negatively correlated with levels of TLR4-responsive miRNAs. Receiver operating characteristic (ROC) curve analysis revealed that a panel of these four miRNAs was sensitive and specific enough to distinguish CAD from non-CAD [area under the curve (AUC)=0.93, 95% CI (confidence interval)=0.99–0.87]. Both ARB and ACEI groups showed increased TLR4-responsive miRNAs and diminished levels of TLR4 protein (P<0.05). Changes in miRNAs and TLR4 levels were greater in the ARB group than in the ACEI group (P<0.05). Circulating TLR4-responsive miRNAs including miR-31, miR-181a, miR-16 and miR-145 were significantly lower in patients with CAD compared with controls and these miRNAs may be involved in the pathogenesis of CAD.
Skip Nav Destination
Article navigation
Research Article|
December 23 2014
Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin–angiotensin system blockade
Mamoru Satoh;
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Correspondence: Dr Mamoru Satoh (email [email protected]).
Search for other works by this author on:
Yuji Takahashi;
Yuji Takahashi
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Tsuyoshi Tabuchi;
Tsuyoshi Tabuchi
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Makiko Tamada;
Makiko Tamada
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Kan Takahashi;
Kan Takahashi
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Tomonori Itoh;
Tomonori Itoh
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Yoshihiro Morino;
Yoshihiro Morino
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Motoyuki Nakamura
Motoyuki Nakamura
*Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Division of Cardioangiology, Nephrology and Endocrinology and Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
July 03 2014
Revision Received:
November 05 2014
Accepted:
November 10 2014
Accepted Manuscript online:
November 10 2014
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2015 Biochemical Society
2015
Clin Sci (Lond) (2015) 128 (8): 483–491.
Article history
Received:
July 03 2014
Revision Received:
November 05 2014
Accepted:
November 10 2014
Accepted Manuscript online:
November 10 2014
Citation
Mamoru Satoh, Yuji Takahashi, Tsuyoshi Tabuchi, Makiko Tamada, Kan Takahashi, Tomonori Itoh, Yoshihiro Morino, Motoyuki Nakamura; Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin–angiotensin system blockade. Clin Sci (Lond) 1 April 2015; 128 (8): 483–491. doi: https://doi.org/10.1042/CS20140417
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |